

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problems Mailbox.**



Europäisches Patentamt
European Patent Office
Office européen des brevets

Publication number:

0 322 068
A1

BE

(2)

EUROPEAN PATENT APPLICATION

(1) Application number: 88202956.4

(6) Int. Cl.4: C07D 277/06, C07K 5/06,
C07D 417/06, A61K 31/425,
A61K 37/02

(2) Date of filing: 19.12.88

(3) Priority: 21.12.87 IT 2312687

Inventor: Carenzi, Angelo
Via Rossini, 9
I-21052 Busto Arsizio (Varese)(IT)

(4) Date of publication of application:
28.06.89 Bulletin 89/26

Inventor: Chiarino, Dario
Via Rivolta, 2
I-20052 Monza (Milano)(IT)

(5) Designated Contracting States:
AT BE CH DE ES FR GB GR IT LI LU NL SE


Inventor: Pellacini, Franco
Piazza Trento Trieste, 20
I-20099 Sesto S. Giovanni (Milano)(IT)

(6) Applicant: ZAMBON GROUP S.p.A.
Via della Chimica, 9
I-36100 Vicenza(IT)

(7) Representative: Marchi, Massimo
c/o Marchi & Mittler s.r.l. Viale Lombardia 20
I-20131 Milano(IT)

(8) Derivatives of thiazolidine-4-carboxylic acid having pharmacological activity.

(9) Compounds of the formula



wherein R, R₁, R₂ and Y have the meanings mentioned in the description, processes for their preparation and their use in the pharmaceutical field are described.

The compounds of formula I are endowed with anti-pyretic, anti-inflammatory, mucolitic and analgesic activity together with good gastric tolerability.

In addition, the compounds of formula I are active in the treatment of ischemic or reperfusion syndromes.

EP 0 322 068 A1

Derivatives of thiazolidine-4-carboxylic acid having pharmacological activity

The present invention relates to N-acyl derivatives of thiazolidine-4-carboxylic acid and more particularly to derivatives of N-acyl-thiazolidine-4-carboxylic acid substituted at position 2 and optionally at the carboxylic group and the corresponding salts with pharmaceutically acceptable acids or bases.


5 The invention also relates to the preparation of such compounds and their use in the pharmaceutical field.

Several thiazolidine-4-carboxylic derivatives substituted at position 2 and having pharmaceutical activity are known.

10 Among these one may mention the compounds endowed with anti-tumoral activity described in the Japanese patent application No. 82/128,625 (Chemical Abstracts, 97:203231b) in the name of Kaken Chemical Co., in which at the position 2 of the thiazolidine ring there is an alkyl, a phenyl, a naphthyl or a benzyl group and the compounds having bacteriostatic and fungistatic activity described in the German patent application No. 2,208,533 (Chemical Abstract, 80:3529s) in the name of Kolmar Laboratories Inc., in which at the position 2 there is an n-undecyl or a benzyl group.

15 The said compounds have a free or saltified carboxylic group at position 4.

15 An object of the present invention are the compounds of the formula



25 wherein

Y is hydrogen or methyl;

when Y = H

R is a radical selected from:

- (6-methoxy-2-naphthyl)-methyl,
- 30 - 1-(4-isobutylphenyl)-ethyl,
- 1-(6-methoxy-2-naphthyl)-ethyl,
- 5-(2,4-difluorophenyl)-2-hydroxyphenyl,
- 2-(3-trifluoromethyl-phenylamino)-phenyl,
- (Z)-5-fluoro-2-methyl-1-(4-methylsulfinylbenzylidene)-1H-inden-3-yl-methyl,
- 35 - 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl-methyl,
- 1-(3-benzoyl-phenyl)-ethyl,
- 2-(2,6-dichlorophenylamino)-benzyl,
- 1-[4-(2-thienyl-carbonyl)-phenyl]-ethyl

when Y = CH₃

40 R is 2-(6-methoxy-2-naphthyl)-ethyl;

R₁ is hydroxy, C₁-C₆ alkoxy, amino, mono- or dialkylamino wherein the alkyl has from 1 to 4 carbon atoms, a radical of an aminoacid of the formula



50 wherein

R₅ is hydrogen;

R₃ is hydrogen, C₁-C₆ alkyl, optionally substituted by hydroxy, SH, SCH₃, or a phenyl optionally substituted by 1 or 2 hydroxy groups;

n is an integer chosen from 0, 1 and 2;


when $n = 0$, R_5 and R_3 together may also form a $-(CH_2)_3-$ or $-CH_2-S-CH_2-$ group;
 R_4 is hydroxy, C_1-C_6 alkoxy or a radical of an aminoacid or the formula



10 wherein R_5 , R_3 and n have the meanings already mentioned;
 R_2 is an acyl radical of a saturated or unsaturated aliphatic monocarboxylic acid, an aromatic or an arylaliphatic acid having up to 16 carbon atoms, of a heterocyclic monocarboxylic acid having a ring with 5 or 6 members containing 1 or 2 heteroatoms chosen from nitrogen, oxygen or sulphur, or of an aliphatic or aromatic dicarboxylic acid having up to 12 carbon atoms;
15 and their salts with pharmaceutically acceptable acids or bases.
 R_2 is preferably an acyl radical of the following carboxylic acids:
a) pharmaceutically acceptable monocarboxylic acids selected, for example, among acetic, propionic, butyric, isobutyric, pentanoic, hexanoic, tertbutylic, octanoic, decanoic, lauric, lactic, palmitic, thioacetic, pivalic, phenylacetic, phenoxyacetic, glyceric, 2-phenylpropionic, benzoic, 3,5-dimethylbenzoic, cinnamic, 20 sorbic, 2- or 4-hydroxybenzoic, 4-aminosalicylic, 5-bromo-acetylsalicylic, 2,5-dihydroxybenzoic, 4-methoxybenzoic, acetyl salicylic, beta-mercaptopropionic, 4-acetoxybenzoic and 4-acetamidobenzoic acid;
b) pharmaceutically acceptable dicarboxylic acids selected, for example, among tartaric, citric, succinic, malic, phthalic and hydroxyphthalic acid wherein the free carboxylic group is optionally saponified by a pharmaceutically acceptable organic or inorganic base;
25 c) pharmaceutically acceptable heterocyclic acids selected, for example, among 2-pyridine-carboxylic, 3-pyridine-carboxylic and 4-pyridine-carboxylic acid.

The compounds of formula I are endowed with anti-pyretic, anti-inflammatory, mucolitic and analgesic activity and, moreover, they are active in the treatment of ischemic pathologies and in pathologies caused by overproduction of oxidant radicals.

30 The compounds of formula I may be prepared by acylation of the corresponding thiazolidine-4-carboxylic derivatives of the formula




wherein R , R_1 and Y have the meanings already mentioned in connection with formula I;
described in the EP-A-0 254 354 in the name of Zambon S.p.A..

45 The acylation step is performed by treatment of a compound of formula II with a suitable acylating agent in an inert organic solvent, optionally in the presence of an inorganic base such as an alkali carbonate or bicarbonate or of an organic base such as triethylamine.

Examples of suitable acylating agents are the carboxylic acids and the acyl reactive derivatives such as the acyl halides and anhydrides. Examples of suitable solvents are methylene chloride, chloroform, tetrahydrofuran, 1,2-dichloroethane, ethyl acetate, 1,4-dioxane.

50 As an alternative, when preparing the compounds of formula I wherein R_1 is $-N(R_5)-(CH_2)_n-CH(R_3)-CO-R_4$, the acylation reaction may be performed on the corresponding compound of formula II wherein $R = OH$.

The thus obtained N-acylated compound ($I - R_1 = OH$) is then condensed with an aminoacid or a dipeptide of the formula



wherein R_3 , R_4 , R_5 and n have the meanings already mentioned.

This condensation is carried out according to techniques known in the peptides chemistry, for example in the presence of a suitable condensing agent such as dicyclohexylcarbodiimide and N-hydroxybenzotriazole.

The compounds of formula III are aminoacids or esters thereof ($R_4 = OH$, alkoxy) or dipeptides [$R_4 = -N(R_5)-(CH_2)_n-CH(R_3)-COOH$] which are known or can be easily prepared according to known methods, for example by condensation of two aminoacids suitably protected in the presence of dicyclohexylcarbodiimide and N-hydroxybenzotriazole.

The compounds of formula II may be prepared (as described in the above-mentioned EP-A- 0 254 354 of Zambon S.p.A.), by reaction of a carbonyl compound of the formula

10



15

with cysteine.

The carbonyl compounds of formula IV are known compounds or they may be easily prepared by reduction, according to conventional methods, of the corresponding carboxylic acids of the formula

20



when $Y = H$

or by oxidation of the corresponding alcohols of the formula

25



30 The carboxylic acids of formula V are known, pharmaceutically active compounds endowed with anti-pyretic, anti-inflammatory and analgesic activity.

They are known by the following common names:

Ibuprofen [$R = 1-(4\text{-isobutylphenyl})\text{-ethyl}$],

Naproxen [$R = 1-(S)\text{-}(6\text{-methoxy-2-naphthyl})\text{-ethyl}$],

35 Diflunisal [$R = 5\text{-}(2,4\text{-difluorophenyl})\text{-2-hydroxy-phenyl}$],

Flufenamic acid [$R = 2\text{-}(3\text{-trifluoromethylphenylamino)-phenyl}$],

Sulindac [$R = (Z)\text{-}5\text{-fluoro-2-methyl-1-(4-methylsulfinyl-benzylidene)-1H-inden-3-yl-methyl}$],

Indometacin [$R = 1-(4\text{-chlorobenzoyl})\text{-5-methoxy-2-methyl-1H-indol-3-yl-methyl}$],

Ketoprofen [$R = 1-(3\text{-benzoyl-phenyl})\text{-ethyl}$],

40 Diclofenac [$R = 2\text{-}(2,6\text{-dichlorophenylamino)-benzyl}$],

Suprofen [$R = 1\text{-}(4\text{-thienylcarbonyl)-phenyl})\text{-ethyl}$].

Among the compounds IV Nabumetone [$4\text{-}(6\text{-methoxy-2-naphthyl)-butan-2-one}$] is a known drug endowed with anti-inflammatory and analgesic activity.

The compounds of the present invention have several asymmetry centers. Typical asymmetry centers are the carbon atoms on position 2 and 4 in the thiazolidine ring and the carbon atom of the R substituent which is at alpha-position to the thiazolidine ring when R is a radical chosen from

1-(4-isobutylphenyl)-ethyl,

1-(6-methoxy-2-naphthyl)-ethyl,

1-(3-benzoyl-phenyl)-ethyl, and

50 1-[4-(2-thienylcarbonyl)-phenyl]-ethyl.

By suitably selecting the compounds of formula II used in the synthesis of the compounds of formula I it is possible to prepare the compounds of formula I having the desired optical isomerism.

In particular the configuration of the carbon atom at the position 4 of the thiazolidine ring depends on the R or S configuration of the cysteine used in the preparation of the compounds of formula II. Likewise, the configuration of the carbon atom at alpha to position 2 of the thiazolidine ring depends on the R or S configuration of the carbon atom at alpha to the carbonyl group in the compounds of formula IV.

The pharmaceutically acceptable salts of the compounds of formula I may be prepared by usual methods.

The salts with bases are obtained by salification of the carboxylic group on the position 4 of the thiazolidine ring ($R_1 = OH$) or of the free carboxylic group when R_2 is an acyl from a bicarboxylic acid or also by salification of carboxylic groups optionally present on the R_1 substituent or of other acid functions optionally present on the R_2 substituent.

5 Typical examples of pharmaceutically acceptable bases are the alkali and earth-alkaline metals such as Na, K, Ca and Mg, and the organic bases such as 2-amino-ethanol, trihydroxymethyl-aminomethane, glucosamine, lysine and arginine.

The salts with acids are obtained by salification of amino groups optionally present on the R_1 and R_2 substituents. Examples of useful acids are the pharmaceutically acceptable fatty acids and mineral acids.

10 As mentioned above the compounds of formula I are endowed with valuable pharmacological properties.

They, in fact, are endowed with anti-pyretic, anti-inflammatory, mucolitic and analgesic action.

Compared with the acids of formula V, the compounds of formula I show a similar profile as far as the anti-pyretic, anti-inflammatory and analgesic action is concerned, in terms of both quality and quantity.

15 A salient difference is indeed the gastric tolerability which is a serious drawback of many acids of formula V but which is very good for the compounds of the present invention.

In addition, the compounds of the present invention proved to be active as mucolytics and in the treatment of ischemic and reperfusion syndromes (M. Bernier et al., Circulation Research, 58 331-340, 1986) concerning various tissues and parenchymas (for example, by preventing reperfusion and reinfarction arrhythmias) and in the treatment of parenchymal alterations due to an overproduction of oxidant radicals by endogenous and exogenous factors.

The compounds of the present invention proved to be endowed with preventive action on GSH depletion (reduced glutathione).

25 Peculiar and innovative proved to be also the ability of the compounds of formula I in preventing arrhythmias from reperfusion in the post-infarctual and reinfarctual syndromes.

Once the acute phase of infarction has been overcome, the patient, during reperfusion, aided by spontaneous or pharmaceutically-induced thrombolysis or by-pass operations, runs a serious risk of arrhythmias (ectopic beats, tachycardia and ventricular fibrillation) which in many cases can prove fatal.

30 Since the compounds of formula I proved to be well tolerated both by oral route and by endovenous injection, they can therefore be used in human therapy as anti-pyretic, anti-inflammatory, mucolitic and analgesic drugs but most of all as drugs capable of preventing the oxidative injuries and the reperfusion damages in the post-infarction and reinfarction syndrome and also in the ischemic and post-ischemic syndromes, and the injuries by oxidant radicals at the pulmonar, cerebral and intestinal levels.

35 The compounds of the present invention may be administered by oral or rectal routes at doses of from 200 to 4,000 mg/day and by the intravenous route at doses of from 100 to 2,000 mg/day.

For therapeutical purposes the compounds of formula I are preferably incorporated into pharmaceutical dosage forms suitable for the desired administration route such as tablets, dragees, capsules, granules, suppositories, solutions, suspensions and lyophilized compositions to be diluted to obtain injectable liquids.

40 Such pharmaceutical dosage forms are prepared by conventional techniques and, in addition to the selected compound of formula I, they contain solid or liquid inert diluents and carriers and pharmaceutically useful additives such as aggregants, disaggregants, salts for regulating the osmotic pressure, buffers, sweeteners and colouring agents.

Particularly useful in preventing the reinfarction are also slow-release pharmaceutical forms for oral use which are prepared according to conventional techniques.

45 For the purpose of better illustrating the present invention, without limiting it in any way, the following examples are now given.

Example 1

50

3-acetyl-2-[(1R)-1-(4-isobutylphenyl)-ethyl]-thiazolidine-4(R)-carboxylic acid

55 To a suspension of 2-[(1R)-1-(4-isobutylphenyl)-ethyl]-thiazolidine-4(R)-carboxylic acid (3 g; 0.010 mol) in tetrahydrofuran (5 ml) a solution of NaHCO₃ (3 g) in water (50 ml) is slowly added.

To the thus obtained solution, kept under stirring at room temperature, acetic anhydride (2.13 ml; 0.021 mol) is added dropwise.

After two hours, ethyl acetate (50 ml) is added.

The organic phase is separated. The aqueous phase is acidified with hydrochloric acid and extracted with ethyl acetate.

After drying on sodium sulphate and evaporation of the solvent a crude product is obtained (3.7 g) which is purified by chromatography on silica gel eluent with methylene chloride:ethyl acetate:acetic acid = 6:4:1, yielding 3-acetyl-2-[(1R)-1-(4-isobutylphenyl)-ethyl]-thiazolidine-4(R)-carboxylic acid (2.4 g) as a solid which is crystallized from terbutyl-methyl-ether.

m.p. = 150 - 153 °C

$[\alpha]_D^{20} = -64.5^\circ\text{C}$ (c = 1, DMF)

$^1\text{H-NMR}$ (200 MHz, CDCl_3): delta (ppm): 0.88 [d, 6H, $(\text{CH}_3)_2\text{CH}$, $J = 4.9\text{ Hz}$]; 1.35 (d, 3H, $\text{CH}_3\text{-CH}$, $J = 7.1\text{ Hz}$); 1.84 [m, 1H, $(\text{CH}_3)_2\text{CH}$]; 2.28 (s, 3H, CH_3CO); 2.44 (d, 2H, PhCH_2 , $J = 7.2\text{ Hz}$); 3.05 (dq, 1H, CH_3CH); 3.20 (dd, 1H, $\text{H}_B\text{-C-S}$, $J_{AB} = 12.4\text{ Hz}$, $J_{BX} = 8.8\text{ Hz}$); 3.55 (dd, 1H, $\text{H}_A\text{-C-S}$, $J_{AB} = 12.4\text{ Hz}$, $J_{AX} = 8.9\text{ Hz}$); 4.95 (dd, 1H, $\text{H}_X\text{-C-COO}$, $J_{AX} = 8.9\text{ Hz}$, $J_{BX} = 8.8\text{ Hz}$); 5.07 (d, 1H, S-CH-N , $J = 8.8\text{ Hz}$); 7.11 (s, 4H, aromatics).

15

Example 2

20

3-acetyl-2-[(1S)-1-(4-isobutylphenyl)-ethyl]-thiazolidine-4(R)-carboxylic acid

Working as described in Example 1 and using 2-[(1S)-1-(4-isobutylphenyl)-ethyl]-thiazolidine-4(R)-carboxylic acid (10 g; 0.034 mol) as the starting product, a crude product (10.3 g) is obtained which is crystallized twice from isopropyl ether until a pure product (7.1 g; yield 62%) is obtained.

m.p. = 131 - 133 °C

$[\alpha]_D^{20} = -210.8^\circ\text{C}$ (c = 1, DMF)

$^1\text{H-NMR}$ (200 MHz, CDCl_3): delta (ppm): 0.85 [d, 6H, $(\text{CH}_3)_2\text{CH}$]; 1.42 (s, 3H, $\text{CH}_3\text{-CO}$); 1.45 [d, 3H, $(\text{CH}_3)_2\text{CH}$, $J = 7.1\text{ Hz}$]; 1.81 [m, 1H, $(\text{CH}_3)_2\text{CH}_2\text{CH}$]; 2.42 (d, 2H, PhCH_2 , $J = 7.1\text{ Hz}$); 2.90 (dq, 1H, $\text{CH}_3\text{-CH-Ph}$); 3.27 (dd, 1H, $\text{S-CH}_3\text{-CH}_x$, $J_{AB} = 12.6\text{ Hz}$, $J_{BX} = 8.8\text{ Hz}$); 3.91 (dd, 1H, $\text{S-CH}_A\text{-CH}_x$, $J_{AB} = 12.6\text{ Hz}$, $J_{AX} = 8.4\text{ Hz}$); 4.8 (d, 1H, Ph-CH-CH_x , $J = 10.2\text{ Hz}$); 4.88 (dd, 1H, $\text{S-CH}_2\text{-CH}_x$, $J_{AX} = 8.4\text{ Hz}$, $J_{BX} = 8.9\text{ Hz}$); 7.10 (s, 4H, aromatics).

35

Example 3

N-(3-acetyl-2-[(1S)-1-(4-isobutylphenyl)-ethyl]-thiazolidine-4(R)-carbonyl)-beta-alanine ethyl ester

40

To a solution of N-(2-[(1S)-1-(4-isobutylphenyl)-ethyl]-thiazolidine-4(R)-carbonyl)-beta-alanine ethyl ester hydrochloride (2 g; 0.0048 mol) in methylene chloride (30 ml), triethylamine (13 ml; 0.0094 mol) is added under stirring and at 0 °C and, after that, acetyl chloride (0.34 g; 0.0048 mol).

The temperature of the reaction mixture is allowed to rise to the room temperature and the mixture is then kept under stirring for two hours.

Methylene chloride is evaporated to dryness and the residue is treated with ethyl ether and a 5% solution of hydrochloric acid. The phases are separated and the ethereal phase is washed with a 5% solution of sodium bicarbonate and then with water.

After drying on sodium sulphate and evaporation of the solvent, an oil (1.8 g) is obtained which consists mainly (91%) of the desired product (yield, 72%). An analytically-pure sample is obtained by chromatography on a silica gel column; eluent, methylene chloride:ethyl acetate = 6:4.

$[\alpha]_D^{20} = -141.8^\circ\text{C}$ (c = 1, DMF)


$^1\text{H-NMR}$ (200 MHz, DMSO-d_6): delta (ppm): 0.84 (d, 3H, $\text{CH}_3\text{-CH-CH}_3$, $J = 6.6\text{ Hz}$); 0.86 (d, 3H, $\text{CH}_3\text{-CH-CH}_3$, $J = 8.8\text{ Hz}$); 1.29 (t, 3H, $\text{CH}_3\text{CH}_2\text{O}$, $J = 7.1\text{ Hz}$); 1.40 (s, 3H, CH_3CO^+); 1.40 (d, 3H, CH_3CHPh , $J = 7.0\text{ Hz}$); 1.84 (s, 3H, CH_3CO^+); 1.80 (m, 1H, $\text{CH}_3\text{-CH-CH}_3$); 2.40 (d, 2H, CH_2Ph , $J = 7.3\text{ Hz}$); 2.50 (m, 2H, CH_2COO); 2.95-3.14 (m, 2H, NH-CH_2); 3.39-3.76 (m, 2H, $\text{S-CH-CH} + \text{CH-CH}_3$); 3.92-4.06 (m, 1H, S-CH-CH_3).

* = the acetamido signal is split into two parts by the presence of sin-anti conformers.

CH); 4.14 (q, 2H, OCH₂, J = 7.1 Hz); 4.78 (d, 1H, S-CH-N, J = 10.4 Hz); 4.90 (dd, 1H, N-CH-CO); 7.02 (s, 4H, aromatics); 7.62 (m, 1H, NH).

5 Claims

1) A compound of the formula



wherein

Y is hydrogen or methyl;

when Y = H

20 R is a radical chosen from:


- (6-methoxy-2-naphthyl)-methyl,
- 1-(4-isobutylphenyl)-ethyl,
- 1-(6-methoxy-2-naphthyl)-ethyl,
- 5-(2,4-difluorophenyl)-2-hydroxyphenyl,
- 2-(3-trifluoromethyl-phenylamino)-phenyl,
- (Z)-5-fluoro-2-methyl-1-(4-methylsulfinylbenzylidene)-1H-inden-3-yl-methyl,
- 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl-methyl,
- 1-(3-benzoyl-phenyl)-ethyl,
- 2-(2,6-dichlorophenylamino)-benzyl,
- 1-[4-(2-thienyl-carbonyl)-phenyl]-ethyl,

30 when Y = CH₃

R is 2-(6-methoxy-2-naphthyl)-ethyl;

R₁ is hydroxy, C₁-C₆ alkoxy, amino, mono- or dialkylamino wherein the alkyl has from 1 to 4 carbon atoms, a radical of an aminoacid of the formula

35



40

wherein

R₅ is hydrogen;


45 R₂ is hydrogen, C₁-C₆ alkyl, optionally substituted by hydroxy, SH, SCH₃, or a phenyl optionally substituted with 1 or 2 hydroxy groups;

n is an integer chosen from 0, 1 and 2;

when n = 0, R₅ and R₂ together may also form a -(CH₂)₃- or -CH₂-S-CH₂- group;

R₄ is hydroxy, C₁-C₆ alkoxy or a radical of an aminoacid of the formula

50



55


wherein R₅, R and n have the meanings already mentioned;

R₂ is an acyl radical of a saturated or unsaturated, aliphatic monocarboxylic acid, an aromatic or an arylaliphatic acid having up to 16 carbon atoms, or a heterocyclic monocarboxylic acid having a ring with 5

or 6 members containing 1 or 2 heteroatoms chosen from nitrogen, oxygen or sulphur, or of an aliphatic or aromatic dicarboxylic acid having up to 12 carbon atoms;
and their salts with pharmaceutically acceptable acids or bases.

2) A compound according to claim 1 wherein R is 1-(4-isobutylphenyl)-ethyl.
 6 3) A compound according to claim 1 wherein R is 1-(6-methoxy-2-naphthyl)-ethyl.
 4) A compound according to claim 1 wherein R is 1-(3-benzoylphenyl)-ethyl.
 5) A compound according to claim 1 wherein R₁ is hydroxy.
 6) A compound according to claim 1 wherein R₁ is C₁-C₆ alkoxy.
 7) A compound according to claim 1 wherein R₂ is an acyl of:
 10 a) a pharmaceutically acceptable monocarboxylic acid chosen from acetic, propionic, butyric, isobutyric, pentanoic, hexanoic, tertbutylacetic, octanoic, decanoic, lauric, lactic, palmitic, thiolactic, pivalic, phenylacetic, phenoxyacetic, glyceric, 2-phenylpropionic, benzoic, 3,5-dimethylbenzoic, cinnamic, sorbic, 2- or 4-hydroxybenzoic, 4-aminosalicylic, 5-bromo-acetylsalicylic, 2,5-dihydroxybenzoic, 4-methoxybenzoic, acetylsalicylic, beta-mercaptopropionic, 4-acetoxybenzoic and 4-acetamidobenzoic acid;
 15 b) a pharmaceutically acceptable dicarboxylic acid chosen from tartaric, citric, succinic, malic, phthalic and hydroxyphthalic acid wherein the free carboxylic group is optionally sallified by a pharmaceutically acceptable organic or inorganic base;
 c) a pharmaceutically acceptable heterocyclic acid selected among 2-pyridinecarboxylic, 3-pyridinecarboxylic and 4-pyridinecarboxylic acid.
 20

8) A compound according to claim 1 in which R₁ is hydroxy, in the form of sodium salt.
 9) A compound according to claim 1 in which the carbon atom at the position 4 of the thiazolidine ring has configuration R.
 25 10) A process for the preparation of the compounds according to claim 1, which comprises the acylation of a compound of the formula



35 wherein R, R₁ and Y have the meanings already mentioned in claim 1,
with a suitable acylating agent in an inert organic solvent, optionally in the presence of an organic or inorganic base.
 11) A pharmaceutical composition comprising a compound according to claim 1 as the active ingredient together with inert solid or liquid carriers or diluents and, optionally, with additives for pharmaceutical use.

40

45

50

55



DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl.4)
A	EP-A-0 169 581 (BOEHRINGER BIOCHEMIA ROBIN S.p.A.) * Claims 1,5 * ---	1,11	C 07 D 277/06 C 07 K 5/06 C 07 D 417/06 A 61 K 31/425 A 61 K 37/02
A	JOURNAL OF MEDICINAL CHEMISTRY, vol. 19, no. 8, August 1976, pages 1002-1007, Washington, D.C., US; B. PAUL et al.: "Cysteine derivatives with reactive groups as potential antitumor agents" ---		
P, X D	EP-A-0 254 354 (ZAMBON S.p.A.) * Claims * -----	1-11	

TECHNICAL FIELDS
SEARCHED (Int. Cl.4)

C 07 D 277/00
C 07 K 5/00

The present search report has been drawn up for all claims

Place of search	Date of completion of the search	Examiner
THE HAGUE	17-03-1989	HENRY J.C.

CATEGORY OF CITED DOCUMENTS

X : particularly relevant if taken alone
Y : particularly relevant if combined with another document of the same category
A : technological background
O : non-written disclosure
P : intermediate document

T : theory or principle underlying the invention

E : earlier patent document, but published on, or after the filing date

D : document cited in the application

L : document cited for other reasons

& : member of the same patent family, corresponding document